4- Thursday Pharmacotherapy News – 12th August

1 – A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections

• This article critically evaluates common Pseudomonas aeruginosa resistance mechanisms and the properties newer β-lactam antimicrobials possess to evade these mechanisms.
• An extensive PubMed, Google Scholar, and ClinicalTrials.gov search was conducted (January 1995 to July 2020) to identify relevant literature on epidemiology, resistance mechanisms, antipseudomonal agents, newer β-lactam agents, and clinical data available pertaining to P aeruginosa.
• Newer agents, including ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam, and cefiderocol, are useful for the treatment of MDR P aeruginosa infections.
• These agents offer improved efficacy and less toxicity compared with aminoglycosides and polymyxins and can be used for pathogens that are resistant to first-line antipseudomonal β-lactams.
• Selection of one agent over another should consider availability, turnaround of susceptibility testing, and product cost.

Source: SAGE Journal

2 – Netarsudil for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Literature Review

• This study aims to evaluate netarsudil’s role as first-line therapy for the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT).
• Evidence demonstrates that netarsudil is inferior to prostaglandin analogues and noninferior to topical β-blockers in the treatment of OAG and OHT.
• Hyperemia is a common adverse drug reaction, which often resolves after medication discontinuation.
• Additional phase III clinical trials and evidence-based guidelines are necessary to determine netarsudil’s position in OAG and OHT management.

Source: SAGE Journal

3 – Hydroxychloroquine-Induced Premature Ventricular Contractions in a Patient With COVID-19 Disease

• The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 poses a serious international public health concern.
• Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases.
• However, evidence of efficacy remains limited, and serious adverse effects had already been reported in patients with COVID-19.1
• In this report, they describe the first case of premature ventricular contractions (PVCs) linked to HCQ use.

Source: SAGE Journal

4- Bamlanivimab Use in Mild-to-Moderate COVID-19 Disease: A Matched Cohort Design

• Bamlanivimab (LY-CoV555; BAM), a monoclonal antibody therapy for mild-to-moderate Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2), has been granted an Emergency Use Authorization (EUA) in the United States.
• The goal was to determine if BAM prevented emergency department (ED) visits, hospitalizations for SARS-CoV-2, or death within 60 days of a positive SARS-CoV-2 viral test.
• BAM infusion for mild-to-moderate SARS-CoV-2 infection in outpatients significantly prevented subsequent ED visits, hospitalizations, and death from SARS-CoV-2

Source: ACCP

5 – Patient Perceptions of a Student-Led Remote Hypertension Education Program

• The COVID-19 pandemic has drastically changed healthcare, promoting a shift to remote services. Managing chronic conditions, like hypertension, became increasingly difficult due to limited access to care.
• During these unprecedented times, two community pharmacies collaborated with a pharmacy school to develop a new remote program to encourage patient management of a chronic disease state.
• The primary objective was to describe patient perceptions of participating in a student-led, remote hypertension education program.
• The secondary objective was to gain insight on perceptions of the program’s impact on current lifestyle.
• Participants had an overwhelmingly positive experience completing the program.
• Utilizing students for development and implementation allowed the pharmacies to offer an additional clinical service and was a factor that impacted patient engagement and participation.

Source: ACCP

6 – Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction

• Although intravenous (IV) bisphosphonates are first-line medications for the management of hypercalcemia, studies examining their use in patients with preexisting renal dysfunction are limited.
• The objective of this study is to describe the safety and efficacy of pamidronate and zoledronic acid in the treatment of hypercalcemia in patients with baseline renal dysfunction.
• The analysis suggests an association between IV bisphosphonates and increased rates of SCr elevations among patients with preexisting renal dysfunction.
• Future prospective studies are necessary to elucidate these findings.

Source: SAGE Journal

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News